drug · protein

TERIPARATIDE

Phase 2updated 3mo ago

by $AMPH Amphastar Pharmaceuticals, Inc.🔗 ChEMBL

Phase 2

community read0 votes

🐶 often sniffed alongside

top 2

Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 8 investigational indications.

targets

Parathyroid hormone/parathyroid hormone-related peptide receptor

all catalysts(0)

nothing on the calendar yet

Trials studying TERIPARATIDE

phase3A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidismrecruitingn=12
phase3A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidismrecruitingn=36
—A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)recruitingn=10
—A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeedingrecruitingn=50
—Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidismapproved for marketing
phase3To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracturenot yet recruitingn=282
—Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Womencompletedn=22,054
phase3Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fracturescompletedn=34

more trials →

News(1)

STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more
A U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching an agreement allowing Teva to market a generic ‌version of Forteo
stat · 1mo ago

brand

TERIPARATIDE

trade names

Bonsity, Forsteo, Forteo, Kauliv, Livogiva, Movymia

generic

TERIPARATIDE

MOA

12.1 Mechanism of Action Endogenous 84-amino acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. Physiological actions of PTH include regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption. The biological actions of PTH and teriparatide are mediated through binding to specific high-affinity cell-surface receptors. Teriparatide and the 34 N-terminal amino acids of PTH bind to these receptors with the same affinity and have the same physiological actions on bone and kidney. Teriparatide is not expected to accumulate in bone or other tissues. The skeletal effects of teriparatide depend upon the pattern of systemic exposure. Once-daily administration of teriparatide stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity. In monkey studies, teriparatide improved trabecular microarchitecture and increased bone mass and strength by stimulating new bone formation in both cancellous and cortical bone. In humans, the anabolic effects of teriparatide manifest as an increase in skeletal mass, an increase in markers of bone formation and resorption, and an increase in bone strength. By contrast, continuous excess of endogenous PTH, as occurs in hyperparathyroidism, may be detrimental to the skeleton because bone resorption may be stimulated more than bone formation.

indication

1 INDICATIONS AND USAGE Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )

phase

phase_2

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 29m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · protein

save

TERIPARATIDE

Phase 2updated 3mo ago

by $AMPH Amphastar Pharmaceuticals, Inc.🔗 ChEMBL

Phase 2

community read0 votes

🐶 often sniffed alongside

top 2

Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 8 investigational indications.

targets

Parathyroid hormone/parathyroid hormone-related peptide receptor

all catalysts(0)

nothing on the calendar yet

Trials studying TERIPARATIDE

more trials →

News(1)

STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more
A U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching an agreement allowing Teva to market a generic ‌version of Forteo
stat · 1mo ago

brand

TERIPARATIDE

trade names

Bonsity, Forsteo, Forteo, Kauliv, Livogiva, Movymia

generic

TERIPARATIDE

MOA

indication

phase

phase_2

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 29m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

TERIPARATIDE

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TERIPARATIDE

News(1)

Report a data issue

comments(0)

TERIPARATIDE

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TERIPARATIDE

News(1)

Report a data issue

comments(0)